Dear all,
A new analysis, co-authored by Andrew Hill and featured in The Lancet, shows that lenacapavir — a long-acting injectable for HIV prevention — could be produced for as little as $25 per person per year. This breakthrough has the potential to transform global HIV prevention efforts.
However, lenacapavir remains out of reach for most due to Gilead’s patent monopoly and high pricing strategies. Supported by the Make Medicines Affordable campaign, the study reveals how intellectual property barriers and lack of generic competition keep prices high and limit access, particularly in low- and middle-income countries.
The analysis urges governments, civil society, and global funders to act now — to demand fair pricing, remove patent barriers, and ensure equitable access for all in the fight to end HIV.
Read the story: Make Medicines Affordable
Read the preprint: SSRN
Best wishes,
Morgane and the ITPC team